Ovo Labs

Executive Summary

Ovo Labs is a UK-based biotechnology company founded in 2018 that aims to address the core biological cause of age-related fertility decline—poor egg quality—which significantly limits the success of in vitro fertilization (IVF). Despite advances in assisted reproductive technology, IVF success rates remain low for women over 35, a growing demographic seeking fertility treatments. Ovo Labs’ novel therapeutic approach targets mitochondrial dysfunction and other intracellular mechanisms that compromise egg quality, potentially restoring developmental competence and improving live birth outcomes. With over two decades of foundational research from its scientific founders, the company is positioned to address a substantial unmet need in reproductive health. The company is currently in the preclinical stage, focusing on lead optimization and IND-enabling studies. Ovo Labs’ technology has the potential to transform fertility treatment by offering a drug-based solution to improve egg quality, complementing existing IVF procedures. If successful, it could expand the addressable market by enabling older women to achieve higher success rates with fewer cycles. The company’s location in London provides access to a leading fertility research ecosystem and a large patient population. While early-stage, Ovo Labs represents a promising therapeutic innovation in the rapidly growing fertility space.

Upcoming Catalysts (preview)

• H2 2026Series A Funding Round70% success
• Q1 2027First-in-Human Clinical Trial Initiation40% success
• Q4 2026Strategic Partnership with Major Fertility Clinic Network50% success